^
Association details:
| Biomarker: | ER positive + ESR1 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | rupitasertib (DIACC3010) (AKT inhibitor, p70S6K inhibitor, AKT1 inhibitor, AKT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4477 / 2 - DIACC3010, optimized inhibitor of S6 kinase, combined with endocrine therapy, has potent antitumor activity in treatment-resistant ER-positive HER2-negative metastatic breast cancer
Published date:
03/15/2023
Excerpt:
The current analysis focused on patients with ER+ HER2-negative MBC and aimed to explore the efficacy of DIACC3010 according to ESR1 mutational status....Median progression free survival was 5.6 months in patients with ESR1 mutations, and 2.6 months in patients with ESR1 wild-type tumors.
